A Closer Look at Rein Therapeutics Inc (RNTX)’s Operating Margin

Nora Barnes

A share price of Rein Therapeutics Inc [RNTX] is currently trading at $1.42, down -18.86%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RNTX shares have gain 7.58% over the last week, with a monthly amount glided 19.33%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Rein Therapeutics Inc [NASDAQ: RNTX] stock has seen the most recent analyst activity on September 22, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $10. Previously, Rodman & Renshaw started tracking the stock with Buy rating on January 28, 2025, and set its price target to $8. On July 24, 2017, William Blair initiated with a Outperform rating. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $20 on July 24, 2017. BofA/Merrill initiated its recommendation with a Buy and recommended $19 as its price target on July 24, 2017.

Rein Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.04 and $4.15. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Rein Therapeutics Inc [NASDAQ: RNTX] shares were valued at $1.42 at the most recent close of the market. An investor can expect a potential return of 322.54% based on the average RNTX price forecast.

Analyzing the RNTX fundamentals

To continue investigating profitability, this company’s Return on Assets is posted at -0.93, Equity is -1.9 and Total Capital is -1.23.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3467 points at the first support level, and at 1.2733 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5667, and for the 2nd resistance point, it is at 1.7133.

Ratios To Look Out For

To put it in perspective, the Current Ratio for Rein Therapeutics Inc [NASDAQ:RNTX] is 0.86. Further, the Quick Ratio stands at 0.86, while the Cash Ratio is 0.74.

Transactions by insiders

Recent insider trading involved Voss Capital, LP, 10% Owner, that happened on Oct 28 ’25 when 0.18 million shares were purchased. 10% Owner, Voss Capital, LP completed a deal on Oct 27 ’25 to buy 97482.0 shares. Meanwhile, 10% Owner Voss Capital, LP bought 30176.0 shares on Oct 24 ’25.

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.